A total of 27 out of the 29 evaluated patients (93%) who received the topical gel, dubbed R327G, for 14 days hit the primary efficacy endpoint in the trial, Recce said in a Feb. 19 release.
A study comparing a new topical gel formulation of oxybutynin to placebo has confirmed its efficacy and tolerability for treating overactive bladder. New formulations of oxybutynin have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results